Selfotel

Selfotel (CGS-19755) is a drug which acts as a competitive NMDA antagonist, directly competing with glutamate for binding to the receptor.^[1] Initial studies showed it to have anticonvulsant, anxiolytic, analgesic and neuroprotective effects,^[2][3] and it was originally researched for the treatment of stroke,^[4] but subsequent animal and human studies showed phencyclidine-like effects,^[5][6][7][8] as well as limited efficacy and evidence for possible neurotoxicity under some conditions,^[9][10][11] and so clinical development was ultimately discontinued.^[12][13]

Selfotel

Clinical data
Other names	Selfotel
Legal status
Legal status	In general: legal
Identifiers
IUPAC name (2S,4R)-4-(phosphonomethyl)piperidine-2-carboxylic acid
CAS Number	110347-85-8 Y
PubChem CID	68736
IUPHAR/BPS	4155
ChemSpider	61982 N
UNII	4VGJ4A41L2
KEGG	D02410 Y
ChEMBL	ChEMBL39664 N
CompTox Dashboard (EPA)	DTXSID5045675
Chemical and physical data
Formula	C7H14NO5P
Molar mass	223.165 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN[C@@H](C[C@@H]1CP(=O)(O)O)C(=O)O
InChI InChI=1S/C7H14NO5P/c9-7(10)6-3-5(1-2-8-6)4-14(11,12)13/h5-6,8H,1-4H2,(H,9,10)(H2,11,12,13)/t5-,6+/m1/s1 N Key:LPMRCCNDNGONCD-RITPCOANSA-N N
NY (what is this?)  (verify)